Title

Rising and higher healthcare-resource-utilization (HCRU) and costs of Nonalcoholic Fatty Liver Disease (NAFLD)/ Nonalcoholic Steatohepatitis (NASH) patients with advanced liver disease-a US real-world-analysis.

Document Type

Conference Proceeding

Publication Date

3-2019

Publication Title

Hepatol Int

Abstract

Background: NAFLD/NASH may progress to advanced-liver-diseases (ALD): compensated-cirrhosis (CC), decompensated-cirrhosis (DCC), hepatocellular-carcinoma (HCC) and liver-transplant (LT). We characterize the comorbidities, HCRU and costs among NAFLD/ NASH ALD patients. Methods: NAFLD/NASH patients aged ≥18 years from 2006 to 2016 were identified retrospectively from a large US commercial and Medicare healthcare claims database using ICD-9/10-CM codes. Following the initial NAFLD/NASH diagnosis, development of ALD was identified using first diagnosis date for each severity cohort (index date). Eligible patients were followed from index date to earliest of 6 months, progression to different cohort, end of coverage, or end of study period. Within each severity cohort, per member per month values were annualized to calculate the mean annual all-cause HCRU/costs as per 2016 USD. Results: Of 468,017 NAFLD/NASH patients, 1.6% (7665) had CC, 3.4% (15,833) had DCC, 0.09% (428) had HCC, and 0.1% (696) had LT. Comorbidities were high across all ALD cohorts-hypertension (36-50%), hyperlipidemia (36-45%), abdominal pain (34-57%), type 2-diabetes (21-42%). All-cause inpatient (IP) admissions and outpatient (OP) services were significantly higher for NAFLD/NASH patients with ALD than those without ALD (p<0.001), with >50% of DCC and LT patients requiring IP admissions post diagnosis of liver-stage. Mean annual costs post-index among NAFLD/NASH with ALD patients were more than 150% higher compared to NAFLD/NASH without ALD ($35,715 (CC), $181,134 (DCC), $147,401 (HCC), and $300,408 (LT) vs. $22,953 (NAFLD/NASH without ALD) [p<0.001]. Conclusion: Early identification and effective management among NAFLD/NASH patients are needed to reduce the risk of disease progression and subsequent healthcare costs. (Figure Presented)

Volume

13

Issue

(Suppl 1)

First Page

s187

This document is currently not available here.

Share

COinS